By Professor Andrew Lloyd

Journal articles

Walker SJ; Shrestha LB; Lloyd AR; Dawson O; Sheehan Y; Sheehan J; Maduka NBC; Cabezas J; Akiyama MJ; Kronfli N, 2024, 'Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit', International Journal of Drug Policy, 126, http://dx.doi.org/10.1016/j.drugpo.2024.104386

Winter RJ; Griffin S; Sheehan Y; Nguyen W; Stoové M; Lloyd AR; Thompson AJ, 2024, 'People in community corrections are a population with unmet need for viral hepatitis care', eClinicalMedicine, 70, http://dx.doi.org/10.1016/j.eclinm.2024.102548

Sheehan Y; Grebely J; Lloyd AR, 2024, 'Reply to: “ ‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues”', Journal of Hepatology, 80, pp. e107 - e108, http://dx.doi.org/10.1016/j.jhep.2023.10.020

Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM, 2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofad637

Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C, 2024, 'Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial', Brain, Behavior, and Immunity, 115, pp. 191 - 200, http://dx.doi.org/10.1016/j.bbi.2023.10.012

Adhikari A; Abayasingam A; Brasher NA; Kim HN; Lord M; Agapiou D; Maher L; Rodrigo C; Lloyd AR; Bull RA; Tedla N, 2024, 'Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes', Journal of Medical Virology, 96, http://dx.doi.org/10.1002/jmv.29381

Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ, 2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895

Kwon JA; Bretaña NA; Kronfli N; Dussault C; Grant L; Galouzis J; Hoey W; Blogg J; Lloyd AR; Gray RT, 2024, 'Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries', Frontiers in Public Health, 12, http://dx.doi.org/10.3389/fpubh.2024.1279572

Wood JG; Heywood AE; Dennington PM; Lloyd AR; Ziegler JB, 2024, 'Trends in intravenous immunoglobulin use in New South Wales, Australia', Internal Medicine Journal, 54, pp. 149 - 156, http://dx.doi.org/10.1111/imj.16175

White P; Abbey S; Angus B; Ball HA; Buchwald DS; Burness C; Carson AJ; Chalder T; Clauw DJ; Coebergh J; David AS; Dworetzky BA; Edwards MJ; Espay AJ; Etherington J; Fink P; Flottorp S; Garcin B; Garner P; Glasziou P; Hamilton W; Henningsen P; Hoeritzauer I; Husain M; Huys ACML; Knoop H; Kroenke K; Lehn A; Levenson JL; Little P; Lloyd A; Madan I; Van Der Meer JWM; Miller A; Murphy M; Nazareth I; Perez DL; Phillips W; Reuber M; Rief W; Santhouse A; Serranova T; Sharpe M; Stanton B; Stewart DE; Stone J; Tinazzi M; Wade DT; Wessely SC; Wyller V; Zeman A, 2023, 'Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis', Journal of Neurology, Neurosurgery and Psychiatry, 94, pp. 1056 - 1063, http://dx.doi.org/10.1136/jnnp-2022-330463

Moallemi S; Lloyd AR; Rodrigo C, 2023, 'Early biomarkers for prediction of severe manifestations of dengue fever: a systematic review and a meta-analysis', Scientific Reports, 13, pp. 17485, http://dx.doi.org/10.1038/s41598-023-44559-9

Ng WH; Liu X; Ling ZL; Santos CNO; Magalhães LS; Kueh AJ; Herold MJ; Taylor A; Freitas JR; Koit S; Wang S; Lloyd AR; Teixeira MM; Merits A; Almeida RP; King NJC; Mahalingam S, 2023, 'FHL1 promotes chikungunya and o’nyong-nyong virus infection and pathogenesis with implications for alphavirus vaccine design', Nature Communications, 14, http://dx.doi.org/10.1038/s41467-023-42330-2

Jones MD; Casson SM; Barry BK; Li SH; Valenzuela T; Cassar J; Lamanna C; Lloyd AR; Sandler CX, 2023, 'eLearning improves allied health professionals' knowledge and confidence to manage medically unexplained chronic fatigue states: A randomized controlled trial', Journal of Psychosomatic Research, 173, pp. 111462, http://dx.doi.org/10.1016/j.jpsychores.2023.111462

Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J, 2023, 'A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644, http://dx.doi.org/10.1016/j.jhep.2023.04.019

Barrios MH; Nicholson S; Bull RA; Martinello M; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Lloyd AR; Konecny P; Mordant F; Catton M; Subbarao K; Caly L; Druce J; Netter HJ, 2023, 'Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19', Microorganisms, 11, http://dx.doi.org/10.3390/microorganisms11081985

Maduranga S; Valencia BM; Sigera C; Adikari T; Weeratunga P; Fernando D; Rajapakse S; Lloyd AR; Bull RA; Rodrigo C; Wijethunga Arachchige S; Valencia Arroyo BM, 2023, 'Genomic Surveillance of Recent Dengue Outbreaks in Colombo, Sri Lanka', Viruses, 15, pp. 1408, http://dx.doi.org/10.3390/v15071408

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36, http://dx.doi.org/10.1016/j.lanwpc.2023.100750

Rockstroh JK; Swan T; Chang J; Elamouri F; Lloyd AR, 2023, 'The path to hepatitis C elimination: who are we leaving behind and why?', Journal of the International AIDS Society, 26, http://dx.doi.org/10.1002/jia2.26136

Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C, 2023, 'Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework', Addiction, 118, pp. 1153 - 1160, http://dx.doi.org/10.1111/add.16137

Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG, 2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, http://dx.doi.org/10.1016/j.ebiom.2023.104545

Selvakumar J; Havdal LB; Drevvatne M; Brodwall EM; Lund Berven L; Stiansen-Sonerud T; Einvik G; Leegaard TM; Tjade T; Michelsen AE; Mollnes TE; Lund-Johansen F; Holmøy T; Zetterberg H; Blennow K; Sandler CX; Cvejic E; Lloyd AR; Wyller VBB, 2023, 'Prevalence and Characteristics Associated with Post-COVID-19 Condition among Nonhospitalized Adolescents and Young Adults', JAMA Network Open, 6, pp. E235763, http://dx.doi.org/10.1001/jamanetworkopen.2023.5763

Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ, 2023, 'Consensus recommendations on the management of hepatitis C in Australia's prisons', Medical Journal of Australia, 218, pp. 231 - 237, http://dx.doi.org/10.5694/mja2.51854

Grebely J; Markus C; Causer LM; Silk D; Comben S; Lloyd AR; Martinez M; Cunningham EB; O'Flynn M; Dore GJ; Matthews S, 2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', The Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7

Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P, 2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469

Gupta M; Balachandran H; Louie RHY; Li H; Agapiou D; Keoshkerian E; Christ D; Rawlinson W; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Bartlett AW; Sasson SC; Ahlenstiel G; Dwyer D; Lloyd AR; Martinello M; Luciani F; Bull RA, 2023, 'High activation levels maintained in receptor-binding domain–specific memory B cells in people with severe coronavirus disease 2019', Immunology and Cell Biology, 101, pp. 142 - 155, http://dx.doi.org/10.1111/imcb.12607

Baird S; Ashley CL; Marsh-Wakefield F; Alca S; Ashhurst TM; Ferguson AL; Lukeman H; Counoupas C; Post JJ; Konecny P; Bartlett A; Martinello M; Bull RA; Lloyd A; Grey A; Hutchings O; Palendira U; Britton WJ; Steain M; Triccas JA, 2023, 'A unique cytotoxic CD4⁺ T cell-signature defines critical COVID-19', Clinical and Translational Immunology, 12, http://dx.doi.org/10.1002/cti2.1463

Thilakanathan C; Kayes T; Di Girolamo J; Nguyen V; Glass A; Manandhar S; Lawler J; Meredith C; Maley M; Lloyd A; Levy MT, 2023, 'Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore', Liver International, 43, pp. 69 - 76, http://dx.doi.org/10.1111/liv.15372

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009

Underwood AP; Gupta M; Wu B-R; Eltahla AA; Boo I; Wang JJ; Agapiou D; Abayasingam A; Reynaldi A; Keoshkerian E; Zhao Y; Brasher N; Walker MR; Bukh J; Maher L; Gordon T; Davenport M; Luciani F; Drummer HE; Lloyd AR; Bull RA, 2023, 'B Cell Signatures and Antibody Imprinting Define HCV Reinfection Outcome', , http://dx.doi.org/10.2139/ssrn.4418620

Valencia BM; Sigera PC; Weeratunga P; Tedla N; Fernando D; Rajapakse S; Lloyd AR; Rodrigo C; Valencia Arroyo BM, 2022, 'Effect of prior Zika and dengue virus exposure on the severity of a subsequent dengue infection in adults', Scientific Reports, 12, pp. 17225, http://dx.doi.org/10.1038/s41598-022-22231-y

Cai C; Samir J; Pirozyan MR; Adikari TN; Gupta M; Leung P; Hughes B; Van der Byl W; Rizzetto S; Elthala A; Keoshkerian E; Palgen JL; Peters T; Nguyen THO; Louie R; Kedzierska K; Gaudieri S; Bull RA; Lloyd AR; Luciani F, 2022, 'Identification of human progenitors of exhausted CD8⁺ T cells associated with elevated IFN-γ response in early phase of viral infection', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-35281-7

Murphy CE; Walker AK; O’Donnell M; Galletly C; Lloyd AR; Liu D; Weickert CS; Weickert TW; ODonnell M, 2022, 'Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases', Translational Psychiatry, 12, pp. 21, http://dx.doi.org/10.1038/s41398-021-01764-2

Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Lloyd AR; Kaldor J; Dore G; Sorrell T; Hudson B; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Lloyd AR; Sultan R; Hudson B; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512, http://dx.doi.org/10.4049/jimmunol.2200272

Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746

Sandler CX; Cvejic E; Valencia BM; Li H; Hickie IB; Lloyd AR, 2022, 'Predictors of Chronic Fatigue Syndrome and Mood Disturbance After Acute Infection', Frontiers in Neurology, 13, http://dx.doi.org/10.3389/fneur.2022.935442

Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Scheibe A; Brahni T; Naik K; Mashabela P; Chan P; Luhmann N; Lloyd AR, 2022, 'The role of low-income and middle-income country prisons in eliminating hepatitis C', The Lancet Public Health, 7, pp. e578 - e579, http://dx.doi.org/10.1016/S2468-2667(22)00119-0

Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; Müllhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Craxì A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannergård A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462

Riaz N; Leung P; Bull RA; Lloyd AR; Rodrigo C, 2022, 'Evolution of within-host variants of the hepatitis C virus', Infection, Genetics and Evolution, 99, pp. 105242, http://dx.doi.org/10.1016/j.meegid.2022.105242

Verveen A; Müller F; Lloyd A; Moss-Morris R; Omland T; Penninx B; Raijmakers RPH; van der Schaaf M; Sandler CX; Stavem K; Wessely S; Wyller VBB; Nieuwkerk P; Knoop H, 2022, 'A research agenda for post-COVID-19 fatigue', Journal of Psychosomatic Research, 154, http://dx.doi.org/10.1016/j.jpsychores.2022.110726

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, 2022, 'Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses', Cell Reports, 38, pp. 110345, http://dx.doi.org/10.1016/j.celrep.2022.110345

Mostafavi H; Tharmarajah K; Vider J; West NP; Freitas JR; Cameron B; Foster PS; Hueston LP; Lloyd AR; Mahalingam S; Zaid A, 2022, 'Interleukin-17 contributes to Ross River virus-induced arthritis and myositis', PLoS Pathogens, 18, http://dx.doi.org/10.1371/journal.ppat.1010185

Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR, 2022, '“That was quick, simple, and easy”: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103456

Casson S; Jones MD; Cassar J; Kwai N; Lloyd AR; Barry BK; Sandler CX, 2022, 'The effectiveness of activity pacing interventions for people with chronic fatigue syndrome: a systematic review and meta-analysis', Disability and Rehabilitation, 45, pp. 3788 - 3802, http://dx.doi.org/10.1080/09638288.2022.2135776

Riaz N; Leung P; Barton K; Smith MA; Carswell S; Bull R; Lloyd AR; Rodrigo C, 2021, 'Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants', BMC Genomics, 22, pp. 148, http://dx.doi.org/10.1186/s12864-021-07460-1

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)', Harm Reduction Journal, 18, pp. 46, http://dx.doi.org/10.1186/s12954-021-00494-4

Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, 98, http://dx.doi.org/10.1016/j.drugpo.2021.103379

Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002

Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the ‘Surveillance and Treatment of Prisoners with Hepatitis C’ project (SToP-C)', Addiction, 116, pp. 2761 - 2769, http://dx.doi.org/10.1111/add.15477

Back to profile page